Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-8201a in Advanced Solid Tumors
NCT02564900Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2015
- Primary completion
- Feb 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of trastuzumab deruxtecan in breast cancer, gastric cancer (GC), gastroesophageal junction adenocarcinoma and 1 more (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Objective Response Rate. Started Sep 2015; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancergastric cancer (GC)gastroesophageal junction adenocarcinomasolid tumor
Beyond the preview
Go deeper on NCT02564900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02564900.